ANNA GRIFFIN

S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

Issues relating to CMMI proposed CMMI Part B demo (81 FR 13229) 340B drug discount program. 21st Century Cures initiative. Implementation of Medicare Pharmaceutical coverage and reimbursement. Follow-on biologies and Medicare Physician Fee schedule rule to blend ASP for biosimilars. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.

H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Accountability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA". S.2912, Trickett Wendler Right to Try Act of 2016. Pandemic Preparedness and CDC strategic national stockpile H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.

S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Accountability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA". S.2912, Trickett Wendler Right to Try Act of 2016. Pandemic Preparedness and CDC strategic national stockpile H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.

H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Sccoubtability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA".

FY 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations annual spending bill; Influenza antiviral allotment with the Centers for Disease Control Strategic National Stockpile issues concerning implementation of Patient Protection and Affordable Care Act Drug pricing H.R. 6, the 21st Century Cures Act Innovations for Healthier Americas Moonshot initiative Precision Medicine Implementation of issues related to Pharmaceutical Quality Security Accountability Act Issues related supply chain Drug safety and pedigree issues Issues related to the 340B program Issues related to follow on biologics

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Accountability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA". S.2912, Trickett Wendler Right to Try Act of 2016. Pandemic Preparedness and CDC strategic national stockpile H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.

S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

Issues to theFY 2015 Department of Labor, Health and Human Services and Education , and Related Agencies Appropriations and issue related to S. Con. Res. 11 and H. Con Res 27; Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Pbulic Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstratins and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B;

21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Reform of 340B program. Advocacy and education regarding HR 6 - 21st Century Cures Act; Implementation issues related to the Pharmaceutical Quality, Security and Accountibilty Act (P.L. 113-54) S. 2007, Preventing Regulatory Overreach to Enhance Care Technology Act of 2014, Cancer Patient Protection; Ongoing issues related to the implementation of the Affordable Care Act - 21st H.R. 6- 21st Century Cures Act; Advocacy on issues related to the Pan-American Health Organization, the 340B during pricing program and Medicare Part B and pandemic planning. Drug pricing under 340B program; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Publaw 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Pubic law 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program; issues related to H.R. 6, the 21st Century CURES Act; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program;

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Pbulic Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstratins and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B;

Issues to theFY 2015 Department of Labor, Health and Human Services and Education , and Related Agencies Appropriations and issue related to S. Con. Res. 11 and H. Con Res 27; Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;

Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.; Issues to theFY 2016 Department of Labor, Health and Human Services and Education , and Related Agencies Appropriations and issue related to S. Con. Res. 11 and H. Con Res

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", HR 1919 "Safeguarding America's Pharmaceuticals Act", Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54), Pharma supply chain issues, Issues related to 340b program; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", HR 1919 "Safeguarding America's Pharmaceuticals Act", Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54), Pharma supply chain issues, Issues related to 340b program; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program

21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Reform of 340B program. Advocacy and education regarding HR 6 - 21st Century Cures Act; Implementation issues related to the Pharmaceutical Quality, Security and Accountibilty Act (P.L. 113-54) S. 2007, Preventing Regulatory Overreach to Enhance Care Technology Act of 2014, Cancer Patient Protection; Ongoing issues related to the implementation of the Affordable Care Act - 21st H.R. 6- 21st Century Cures Act; Advocacy on issues related to the Pan-American Health Organization, the 340B during pricing program and Medicare Part B and pandemic planning. Drug pricing under 340B program; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Publaw 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", HR 1919 "Safeguarding America's Pharmaceuticals Act", Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54), Pharma supply chain issues, Issues related to 340b program; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

H.R. 1908 Intellectual Property and Process Patent Issues S. 515 & H.R. 1260 - Patent Reform Act of 2009

S. 515 & H.R. 1260 - Patent Reform Act of 2009

Patent Settlement Issues; Intellectual Property and Process Patent Issues; H.R. 1908; S. 515 & HR. 1260 - Patent Reform Act of 2009; Monitor legislation regarding brand name and generic pharmaceutical agreement, patent fees, and post-grant review reforms.

H.R. 1908 Intellectual Property and Process Patent Issues S. 515 & H.R. 1260 - Patent Reform Act of 2009

S.515 & H.R. 1260 - Patent Reform Act of 2009

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Medicare issues; payment policies for prescription drugs; implementation of H.R.1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patient Protection and Affordable Care Act; H.R.4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S726/H.R. 1427 Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Compartiveffectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act; American Health Future Act of 2009; Pharmaceutical Import Safety legislation.

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Pandemic Preparedeness: Tamiflu; Advocate on legislative changes in the health care reform bill regarding biosimilars; Monitor changes to outpatient 340B presecription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act; S. 3793, Job Creation and TAx Cuts Act; All healthcare and biotechnology legislation. Stockpiling of antiviral in preparation of a pandemic, HHS Appropriations bill H.R. 1548 - Pathway for Biosimilars Act FDA Approval and Enforcement Issues Cancer Research Issues S. 3686 FY 2011 Appropriations, HHS HCR issues concerning clinical trials Congressional oversight issues Implementation issues related to the Patient Protection and Affordable Care Act H.R. 1 - Pandemic influenza funding H.R. 1105 Omnibus Appropriations Act, Pandemic Funding Issues Food Safety Bill, H.R. 4872 Health Care and Education Reconciliation Act of 2010 H.R. 3974 Viral Hepatitis and LIver Cancer Control and Prevention Act of 2009 H.R. 3590 Patient Projection and Affordable Care Act-FTC issue Ryan White CARE Act reauthorization S. 726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act Educational meetings in Senate with candiate for Patient Centered Outcomes Research Institute Board (PCORI)

Pandemic Preparedeness: Tamiflu; Advocate on legislative changes in the health care reform bill regarding biosimilars; Monitor changes to outpatient 340B presecription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act, and ddraft Senate amendments to the legislation; Labor, Health and Human Services Appropriations bill; H.R. 1548 - Pathway for Biosimilars Act; Health care and biotechnology legislation, including H.R. 3490; Implementation of P.L. 111-148, "Patient Protection and Affordable Care Act" and P.L. 111-152, "Reconciliation Act of 2010", including comparative effectiveness provisions; S. 726/H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; H.R. 1548 - Pathway for Biosimilars Act; Physician payment disclosure including S. 301; Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for Americans Act; H.R. 3590; Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010; Follow on biologics includuing H.R. 154, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life Savings Medicines Act; H.R. 3962, Affordable health care for America Act; Comparative effectiveness legislation including S. 1213; Patient-Centered Outcomes Research Act of 2009; H.R. 3200, America's Health Future Act; H.R. 1548 - Pathway for Dissimilar Act; Legislative changes in the heatlh care reform bill regarding dissimilars; S. 1679 Affordeable Health Choice Act; S.1796, America's Health future Act of 2009; Pharmacuetical import safety legislation. H.R. 1105 Omnibus Appropriations Act of 2010; Supplemental Appropriations Act of 2010, Food Safety Issues concerning clinlical trials; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 H.R. 3590 Patient Protetion and Affordable Care Act - FTC issue Ryan White CARE Act reauthorization

Medicare issues; payment policies for prescription drugs; implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patitient Protection and Affordable Care Act; H.R> 4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S. 726/H.R.1427, Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Comparativ effectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act;, American Health Future Act of 2009; Pharmaceutical Import safety legislation.

Labor HHS appropriations stock piling anti-virals for pandemic influenza; Cancer Research Issues - S.3686/HR__, Labor, HHS Appropriations Bill for FY2011; Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars; H.R.1 - Pandemic influenza funding: H.R. 1105 Omnibus Appropriations Act of 2010, Food Safety Bill, H.R. 4872 Health Care & Education Reconciliation Act of 2010; issues concerning clincial trials; general health care refore (Patient Protection and Affordable Care Act); Congressional oversight issues; FDA approval and enforcement issues; Pandemic preparedness; Tamiflu; Avastin-breast cancer ; following all issues related to health care reform; S.726/HR 1427 - promoting innovation and access to life-saving Medicine Act; HR 1548 - Pathway for Biosimilars Act; General support for Genentech products; monitor and report on issues related to the implementation of health care reform; H.R. 1548 - Pathway for Biosimilars Act;

Labor HHS appropriations stock piling anti-virals for pandemic influenza; Cancer Research Issues - S.3686/HR_, Labor, HHS Appropriations Bill for FY2011; Monitoring the implementation for the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars; H.R.1 - Pandemic influenza funding: H.R.1105 Omnibus Appropriations Act of 2010, Food Safety Bill, H.R. 4872 Health Care& Education Reconciliation Act of 2011; issues concerning clincial trials; general health care reform (Patient Protection and Affordable Care Act); Congressional oversight issues; FDA approval and enforcement issues; Pandemic preparedness; Tamiflu; Avastin-breast cancer; following all issues related to health care reform; S.726/HR 1427 - promotiong innovation and access to life-saving Medicine Act; HR 1548 - Pathway for Biosimilars Act; General support for Genentech products; monitor and report on issues relate to implementation to health care reform; H.R. 1548 - Pathway for Biosimilars Act

S. 565/H.R. 1458 - providing extended coverage for immunosuppressive drugs to beneficiaries under ther Medicare Program that have received a kidney transplant

S. 565/H.R. 1458 - providing extended coverage for immunosuppressive drugs to beneficiaries under ther Medicare Program that have received a kidney transplant

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Medicare issues; payment policies for prescription drugs; implementation of H.R.1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patient Protection and Affordable Care Act; H.R.4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S726/H.R. 1427 Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Compartiveffectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act; American Health Future Act of 2009; Pharmaceutical Import Safety legislation.

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Pandemic Preparedeness: Tamiflu; Advocate on legislative changes in the health care reform bill regarding biosimilars; Monitor changes to outpatient 340B presecription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act, and ddraft Senate amendments to the legislation; Labor, Health and Human Services Appropriations bill; H.R. 1548 - Pathway for Biosimilars Act; Health care and biotechnology legislation, including H.R. 3490; Implementation of P.L. 111-148, "Patient Protection and Affordable Care Act" and P.L. 111-152, "Reconciliation Act of 2010", including comparative effectiveness provisions; S. 726/H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; H.R. 1548 - Pathway for Biosimilars Act; Physician payment disclosure including S. 301; Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for Americans Act; H.R. 3590; Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010; Follow on biologics includuing H.R. 154, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life Savings Medicines Act; H.R. 3962, Affordable health care for America Act; Comparative effectiveness legislation including S. 1213; Patient-Centered Outcomes Research Act of 2009; H.R. 3200, America's Health Future Act; H.R. 1548 - Pathway for Dissimilar Act; Legislative changes in the heatlh care reform bill regarding dissimilars; S. 1679 Affordeable Health Choice Act; S.1796, America's Health future Act of 2009; Pharmacuetical import safety legislation. H.R. 1105 Omnibus Appropriations Act of 2010; Supplemental Appropriations Act of 2010, Food Safety Issues concerning clinlical trials; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 H.R. 3590 Patient Protetion and Affordable Care Act - FTC issue Ryan White CARE Act reauthorization

Medicare issues; payment policies for prescription drugs; implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patitient Protection and Affordable Care Act; H.R> 4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S. 726/H.R.1427, Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Comparativ effectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act;, American Health Future Act of 2009; Pharmaceutical Import safety legislation.

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Medicare issues; payment policies for prescription drugs; implementation of H.R.1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patient Protection and Affordable Care Act; H.R.4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S726/H.R. 1427 Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Compartiveffectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act; American Health Future Act of 2009; Pharmaceutical Import Safety legislation.

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation